$1.14/ day, billed weekly
Cancel anytime

(Ads Free, Unlimited access)

NO CREDIT CARD REQUIRED

Chromocell Therapeutics Corporation (CHRO)CHRO

Chromocell Therapeutics Corporation

$0.87

Delayed price

PASS

BUY Advisory
Profitable SELL
Loss-Inducing SELL

Profit
Loss
PASS (Skip invest)*

Upturn Stock price based out of last close

Time period over

ALL
YEAR
MONTH
WEEK

Time period over

Upturn Advisory Summary

09/18/2024: CHRO (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Upturns

Type: Stock	Upturn Star Rating	Today’s Advisory: PASS
Profit: 0%	Upturn Advisory Performance 1	Avg. Invested days: 0
Profits based on simulation	Stock Returns Performance 1	Last Close 09/18/2024

Type: Stock	Today’s Advisory: PASS
Profit: 0%	Avg. Invested days: 0
Upturn Star Rating	Stock Returns Performance 1
Profits based on simulation Last Close 09/18/2024	Upturn Advisory Performance 1

Key Highlights

Company Size Small-Cap Stock	Market Capitalization 5.34M USD
Price to earnings Ratio -	1Y Target Price 8.5
Dividends yield (FY) -	Basic EPS (TTM) -1.68
Volume (30-day avg) 19206	Beta -
52 Weeks Range 0.58 - 6.00	Updated Date 09/15/2024

Company Size Small-Cap Stock	Market Capitalization 5.34M USD	Price to earnings Ratio -	1Y Target Price 8.5
Dividends yield (FY) -	Basic EPS (TTM) -1.68	Volume (30-day avg) 19206	Beta -
52 Weeks Range 0.58 - 6.00	Updated Date 09/15/2024

Earnings Date

Report Date 2024-08-28	When -
Estimate -	Actual -0.3068

Report Date 2024-08-28

When -

Estimate -

Actual -0.3068

Profitability

Profit Margin -

Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -412.8%

Return on Equity (TTM) -

Valuation

Trailing PE -	Forward PE -
Enterprise Value 4519270	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -3.58
Shares Outstanding 5766700	Shares Floating 1353388
Percent Insiders 75.52	Percent Institutions 9.43

Trailing PE -	Forward PE -	Enterprise Value 4519270	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -3.58	Shares Outstanding 5766700	Shares Floating 1353388
Percent Insiders 75.52	Percent Institutions 9.43

Analyst Ratings

Rating 5	Target Price -	Buy -
Strong Buy 1	Hold -	Sell -
Strong Sell -

Rating 5	Target Price -	Buy -	Strong Buy 1
Hold -	Sell -	Strong Sell -

About Chromocell Therapeutics Corporation

Exchange	NYSE MKT	Headquaters	Freehold, NJ, United States
IPO Launch date	2024-02-16	CEO, CFO, Treasurer & Secretary	Mr. Francis Knuettel II, M.B.A.
Sector	Healthcare	Website	https://www.chromocell.com
Industry	Biotechnology	Full time employees	4
Headquaters	Freehold, NJ, United States
CEO, CFO, Treasurer & Secretary	Mr. Francis Knuettel II, M.B.A.
Website	https://www.chromocell.com
Website	https://www.chromocell.com
Full time employees	4

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.